^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD8 overexpression

i
Other names: CD8, CD8A, cluster of differentiation 8, CD8a Molecule, T-Cell Surface Glycoprotein CD8 Alpha Chain, T-Lymphocyte Differentiation Antigen T8/Leu-2, CD8 Antigen, Alpha Polypeptide (P32), Leu2 T-Lymphocyte Antigen, OKT8 T-Cell Antigen, T-Cell Antigen Leu2, T Cell Co-Receptor, T8 T-Cell Antigen, CD8a Antigen
Entrez ID:
Related biomarkers:
28d
Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma. (PubMed, Front Immunol)
Additionally, the survival analysis revealed that high expression of CD8 was associated with better disease-specific survival and progression-free survival in PDAC patients. These findings highlight the potential of CD8, CD68, and VISTA as diagnostic and prognostic indicators in PDAC.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD68 (CD68 Molecule) • VSIR (V-Set Immunoregulatory Receptor)
|
CD8 overexpression
1m
Concise review: The heterogenous roles of BATF3 in cancer oncogenesis and dendritic cells and T cells differentiation and function considering the importance of BATF3-dependent dendritic cells. (PubMed, Immunogenetics)
BATF3 induces Th9 cell differentiation by binding to the IL-9 promoter through a BATF3/IRF4 complex. One of the latest research findings is the oncogenic function of BATF3, which has been approved and illustrated in several biological processes of proliferation and invasion.
Review • Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IRF4 (Interferon regulatory factor 4) • FOXP3 (Forkhead Box P3) • ITGAE (Integrin Subunit Alpha E) • BATF3 (Basic Leucine Zipper ATF-Like Transcription Factor 3)
|
CD8 overexpression • CD8 expression • FOXP3 overexpression • FOXP3 expression
2ms
Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial. (PubMed, EClinicalMedicine)
Patients underwent neoadjuvant chemoimmunotherapy (sintilimab combined with nab-paclitaxel and carboplatin) for two to three cycles prior to surgical resection of the lung carcinoma and systematic nodal dissection within 30-45 days. Consequently, the treatment landscape for potentially resectable IIIA/IIIB NSCLC could undergo changes. This study did not receive any financial support.
P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8)
|
CD8 overexpression • CD8 expression
|
carboplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel
2ms
Copy number gain of FAM131B-AS2 promotes the progression of glioblastoma by mitigating replication stress. (PubMed, Neuro Oncol)
FAM131B-AS2 emerges as a promising indicator for adjuvant therapy response and could also be a viable candidate for combined immunotherapies against GBMs.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • RPA1 (Replication Protein A1) • USP7 (Ubiquitin Specific Peptidase 7)
|
CD8 overexpression • CD8 expression
2ms
Global burden, risk factors, clinicopathological characteristics, molecular biomarkers and outcomes of microsatellite instability-high gastric cancer. (PubMed, Aging (Albany NY))
Moreover, giving MSI-H tumors are often diagnosed at early stage and have favorable outcomes, less aggressive treatment strategies may be considered in clinical practice. In summary, this panoramic review may assist in design and/or interpretation of clinical trials, provide references in drug development, and constitute complementary information in drafting the clinical practice guideline.
Journal • Tumor mutational burden • Microsatellite instability • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8)
|
HER-2 positive • TP53 mutation • KRAS mutation • TMB-H • PD-L1 overexpression • MSI-H/dMMR • HER-2 overexpression • HER-2 mutation • CD8 overexpression • PD-L1 overexpression + CD8 overexpression • PD-L1 mutation
2ms
Single-cell analysis reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of ovarian cancer. (PubMed, Commun Biol)
Dual IHC staining show that tumor infiltrating CD8 T cells localize in proximity of CXCL12+ tumor area. Moreover, CXCL12 and/or CXCR4 antibodies confirm the immunosuppressive role of CXCL12-CXCR4 in high-stromal tumors.
Journal • Stroma
|
CD8 (cluster of differentiation 8) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
CD8 overexpression • CD8 expression • CXCL12 expression
4ms
MDSCs-derived GPR84 induces CD8 T-cell senescence via p53 activation to suppress the antitumor response. (PubMed, J Immunother Cancer)
These data demonstrated that the transfer of GPR84 from MDSCs to CD8 T cells induces T-cell senescence via the p53 signaling pathway, which could explain the strong immunosuppression of GPR84 endowed to MDSCs.
Journal
|
CD8 (cluster of differentiation 8)
|
CD8 overexpression • CD8 expression
5ms
Unraveling the Dynamics of T Cell-Dependent Bispecific Antibodies in Multiple Myeloma: Multi-Omic Insights from Primary Patient Cells (ASH 2023)
Image analysis revealed that TDB treatment induced T cell-mediated cytotoxicity in four patients, with sub-optimal TDB-induced cytotoxicity observed in two patients, highlighting intrinsic resistance mechanisms to TDB treatment and the need for greater mechanistic understanding. Notably, all patients' effector cells exhibited upregulation of CD69, a T cell activation marker, after 24 hours post-TDB treatment which was sustained for 72 hours. TDB treatment also led to the upregulation of CD25, starting at 24 hours and peaking 72 hours post-treatment.
Clinical • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule) • CD28 (CD28 Molecule) • CD3D (CD3d Molecule) • CD3G (CD3 Gamma Subunit Of T-Cell Receptor Complex)
|
CD8 overexpression • IL2 expression
|
nCounter® PanCancer IO 360™ Panel
8ms
TERT-associated DNA polymerases genes link CAF and CD8+ T cells to improve immunotherapy response rate across multiple cancers (ESMO 2023)
In our phase II clinical trial, 34 liver cancer were enrolled with 3-year follow-up, it also has a satisfactory performance in predicting the ORR (AUC=0.699) and classifies mortality rate (HR=2.3). Conclusions Our findings identify a distinct transcriptional pattern of DNA-pol genes across cancers, which highlighted the role of DNA-pol family genes in predicting the immunotherapy response for the first time, and TERT could be a novel vaccine candidate for improving immunotherapy response.
Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • TERT (Telomerase Reverse Transcriptase)
|
PD-L1 expression • TP53 mutation • KRAS mutation • PD-L1 overexpression • MSI-H/dMMR • PIK3CA mutation • CD8 overexpression • CD8 expression • TERT overexpression
11ms
METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer. (PubMed, Biomark Res)
Overall, METTL3, YTHDF2, and NLRC5 have potential to be the diagnostic and prognostic biomarkers for EC. METTL3 facilitated the m6A modifications of NLRC5 and inhibited its degradation through a YTHDF2-dependent mechanism in EC. Genetic overexpression of METTL3 attenuated the immune evasion of EC by promoting NLRC5-mediated immunosurveillance, suggesting that the METTL3/YTHDF2/NLRC5 axis is a promising target of immunotherapy in EC.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • NLRC5 (NLR Family CARD Domain Containing 5) • METTL3 (Methyltransferase Like 3) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
|
CD8 overexpression • CD8 expression
11ms
TERT-associated DNA polymerases genes link CAF and CD8+ T cells to improve immunotherapy response rate across multiple cancers (ESMO-GI 2023)
Our findings identify a distinct transcriptional pattern of DNA-pol genes across cancers, which highlighted the role of DNA-pol family genes predicting the immunotherapy response for the first time, and TERT could be a novel vaccine candidate for improving immunotherapy response.
Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • TERT (Telomerase Reverse Transcriptase)
|
PD-L1 expression • TP53 mutation • KRAS mutation • PD-L1 overexpression • MSI-H/dMMR • PIK3CA mutation • CD8 overexpression • CD8 expression • TERT overexpression
12ms
HEPATIC TM6SF2 SUPRRESSES NAFLD-HCC THROUGH ACTIVATING ANTITUMOR IMMUNITY (DDW 2023)
Hepatic TM6SF2 protects against NAFLD-HCC development by activating anti-tumor immunity through NF-κB-G-CSF axis to activate cytotoxic CD8+ T cell function. TM6SF2 is a novel therapeutic target to increase response to anti-PD1 immunotherapy in NAFLD-HCC.
PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
|
CD8 overexpression • CD8 expression
12ms
TARGETING SQLE REACTIVATES ANTITUMOR IMMUNITY AND RESCUES IMMUNE CHECKPOINT EFFICACY IN NON-ALCOHOLIC STEATOHEPATITIS-INDUCED HEPATOCELLULAR CARCINOMA (DDW 2023)
SQLE inhibitor terbinafine was given in combination with anti-PD1 therapy in mouse models of NASH-HCC...Conclusions : SQLE induces an impaired antitumor response in NASH-HCC via attenuating tumor-infiltrating CD8 + T cell effector function and augmenting immunosuppressive MDSCs, an effect dependent on cholesterol biosynthesis. SQLE is a promising target in potentiating anti-PD-1 immunotherapy for NASH-HCC.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • GZMB (Granzyme B) • SQLE (Squalene Epoxidase)
|
CD8 overexpression • CD8 expression
1year
The RAF/MEK clamp avutometinib (VS-6766) induces an immunogenic tumor microenvironment and potentiates the efficacy of anti-PD-1 (AACR 2023)
Interestingly, all these pro-immune changes observed with avuto were stronger than those observed with an equivalent dose level of the MEK-only inhibitor trametinib. Furthermore, all complete responders in the avuto + anti-PD-1 group were able to reject a re-challenge with CT26 tumor cells and showed increased CD8 and CD4 effector memory T cells relative to untreated naïve control mice, indicating that avuto + anti-PD-1 treatment induces durable immune memory. These results support clinical evaluation of avutometinib in combination with an anti-PD-1 antibody for treatment of patients with solid tumors harboring MAPK pathway alterations such as KRAS or BRAF mutations.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • B2M (Beta-2-microglobulin) • CD4 (CD4 Molecule) • ARAF (A-Raf Proto-Oncogene) • TAP1 (Transporter 1) • IRF7 (Interferon Regulatory Factor 7) • NCR1 (Natural Cytotoxicity Triggering Receptor 1)
|
KRAS mutation • KRAS G12C • BRAF mutation • KRAS G12D • CD8 overexpression • MHC-II expression
|
Mekinist (trametinib) • avutometinib (VS-6766)
over1year
GITR LIGATION IMPROVES ANTI-PD1-MEDIATED RESTORATION OF HUMAN MMR-PROFICIENT COLORECTAL CARCINOMA TUMOR-DERIVED T CELLS. (PubMed, Cell Mol Gastroenterol Hepatol)
GITR is overexpressed on CD4 and CD8 TIL from pMMR CRC and CRLM. Agonistic targeting of GITR enhances ex vivo human TIL functionality and may therefore be a promising approach for novel mono- or combined immunotherapies in primary pMRR CRC and CRLM.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • FOXP3 (Forkhead Box P3) • ITGAE (Integrin Subunit Alpha E) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
|
MSI-H/dMMR • CD8 overexpression • CD8 expression • CD4 expression • FOXP3 expression
|
Opdivo (nivolumab)
over1year
FOXP3 expression diversifies the metabolic capacity and enhances the efficacy of CD8 T cells in adoptive immunotherapy of melanoma. (PubMed, Mol Ther)
Importantly, their ability to couple glycolysis and OXPHOS allowed them to sustain proliferation under glucose restriction. Our findings demonstrate a hitherto unknown role for FOXP3 in the adaptation of CD8 T cells to TME that may enhance their efficacy in ACT.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • FOXP3 (Forkhead Box P3)
|
CD8 overexpression • CD8 expression • FOXP3 expression
over1year
HOXA11-AS1 Promotes PD-L1-Mediated Immune Escape and Metastasis of Hypopharyngeal Carcinoma by Facilitating PTBP1 and FOSL1 Association. (PubMed, Cancers (Basel))
HOXA11-AS1 promoted PD-L1 expression by upregulating FOSL1 levels through PTBP1, thereby facilitating immune escape, proliferation, and metastasis of HSCC cells.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • PTBP1 (Polypyrimidine Tract Binding Protein 1) • HOXA11 (Homeobox A11) • HOXA11-AS (HOXA11 Antisense RNA)
|
PD-L1 expression • CD8 overexpression • HOXA11 overexpression • PTBP1 overexpression
almost2years
1α,25(OH)D reverses exhaustion and enhances antitumor immunity of human cytotoxic T cells. (PubMed, J Immunother Cancer)
Our findings uncover the pleiotropic effects of 1α,25(OH)D in rescuing the exhausted phenotype of human cytotoxic T cells in patients with tumor and in promoting their antitumor immunity.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD28 (CD28 Molecule)
|
PD-1 expression • CD8 overexpression • CD8 expression • HAVCR2 expression
|
docetaxel
over2years
CD155/TIGIT signaling regulates the effector function of tumor-infiltrating CD8 T cell by NF-κB pathway in colorectal cancer. (PubMed, J Gastroenterol Hepatol)
Suppressing CD155/TIGIT exerted anti-cancer effects against CRC and our findings provided a potential therapeutic approach to treat CRC.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • IL2 (Interleukin 2) • RELA (RELA Proto-Oncogene)
|
CD8 overexpression • CD8 expression • TIGIT overexpression
over2years
[VIRTUAL] Artificial membrane vesicles isolated from mesenchymal stem cells with IL2 overexpression activate CD8 + Tkillers to kill triple negative breast cancer cells (ESGCT 2021)
The use of CIMVsIL2 can be effective in the treatment of triple negative breast cancer, since CIMVsIL2 are able to activate and stimulate the proliferation of Tkillers. However, further studies of CIMVs efficiency in animal tumor models are required.
IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL2 (Interleukin 2)
|
CD8 overexpression • CD8 expression
over2years
Prognosis of Non-small-cell Lung Cancer Patients With Lipid Metabolism Pathway Alternations to Immunotherapy. (PubMed, Front Genet)
In the local-NSCLC cohort, we found that the group with a high number of mutations had a significantly higher tumor mutation burden (TMB) and PD-L1 expression. High mutation status in the lipid metabolism pathway is associated with significantly prolonged progression-free survival (PFS) in NSCLC, indicating that this marker can be used as a predictive indicator for patients with NSCLC receiving ICIs.
Clinical • Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • GZMB (Granzyme B) • GZMA (Granzyme A)
|
PD-L1 expression • PD-L1 overexpression • CD8 overexpression
almost3years
Oncolytic vaccinia virus gene modification and cytokine expression effects on tumor infection, immune response, and killing. (PubMed, Mol Cancer Ther)
VV-A34/IL2v led to higher serum IL-2 and greater tumor expression of death receptor ligand TRAIL, but VV-GMCSF led to higher serum GM-CSF, greater expression of leukocyte chemokines and adhesion molecules, and more neutrophil recruitment. Together, the results show that antitumor activity is similarly increased by viral expression of GM-CSF or IL-2v combined with additional genetic modifications.
Journal • Oncolytic virus
|
CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • FASLG (Fas ligand) • IL2 (Interleukin 2) • CSF2 (Colony stimulating factor 2) • GZMB (Granzyme B) • GZMA (Granzyme A) • PRF1 (Perforin 1)
|
CD8 overexpression • CSF2 expression • CSF2 elevation • IL2 expression
3years
4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. (PubMed, J Immunother Cancer)
Severely exhausted PD-1 CD39 CD8 TILs displayed a distinctly heterogeneous exhaustion and activation status determined by differential 4-1BB expression levels, providing rationale and evidence for immunotherapies targeting co-stimulatory receptor 4-1BB in ovarian cancers.
Journal • PD(L)-1 Biomarker
|
CD8 (cluster of differentiation 8)
|
PD-1 overexpression • CD8 overexpression • CD8 expression • PD-1 elevation • TILs
over3years
[VIRTUAL] Artificial Microvesicles Isolated from Mesenchymal Stem Cells with IL2 Overexpression Activate CD8+ T-Killers to Kill Triple Negative Breast Cancer Cells (ASH 2020)
However, further studies of CIMVs efficiency in animal tumor models are required. This study was supported by the Russian Science Foundation grant 18-74-10044 and the Russian Government Program of Competitive Growth of KFU.
IO biomarker
|
CD8 (cluster of differentiation 8) • CD38 (CD38 Molecule) • CD73 (5'-Nucleotidase Ecto) • CD44 (CD44 Molecule) • IL2 (Interleukin 2) • ENG (Endoglin)
|
CD8 overexpression • CD8 expression